All Comments by Takaomi Saido

  1. Tau Protein Phosphorylation in Diverse Brain Areas of Normal and CRH Deficient Mice: Up-Regulation by Stress.
  2. Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.
  3. TLR2 is a primary receptor for Alzheimer's amyloid β peptide to trigger neuroinflammatory activation.
  4. Amyloid Imaging with AV45 (18F-florbetapir) in a Cognitively Normal AβPP Duplication Carrier.
  5. A Canine Model to Evaluate Efficacy and Safety of γ-Secretase Inhibitors and Modulators.
  6. Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1.
  7. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
  8. Amyloid-β associated volume loss occurs only in the presence of phospho-tau.
  9. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration.
  10. Adaptive responses to alloxan-induced mild oxidative stress ameliorate certain tauopathy phenotypes.
  11. Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms.
  12. Resolving Controversies on the Path to AD Therapeutics
  13. Resolving controversies on the path to Alzheimer's therapeutics.
  14. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation.
  15. Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence.